Estimating the number of patients infected with chronic HCV in the United States who meet highest or high-priority treatment criteria

American Journal of Public Health

Volumn 105, Issue 7, 2015, Pages 1285-1289

  Xu, Fujie ^a   Leidner, Andrew J ^a   Tong, Xin ^a   Holmberg, Scott D ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

COMORBIDITY; COMPLICATION; FEMALE; HEALTH CARE PLANNING; HEPATITIS C, CHRONIC; HUMAN; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NUTRITION; PRACTICE GUIDELINE; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ANTIVIRAL AGENTS; COMORBIDITY; FEMALE; HEALTH PRIORITIES; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NUTRITION SURVEYS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 84930826898     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2015.302652     Document Type: Review

References (21)

1. Chao D, Botwin G, Morgan TR. Update on recently approved treatments for hepatitis C. Curr Treat Options Gastro-enterol. 2014;12(2):211-228.
2. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983-1992.
3. American Association for the Study of Liver Diseases and Infectious Diseases Society of America. When and in whom to initiate HCV therapy. Available at: http://www.hcvguidelines.org/node/91. Accessed December 5, 2014.
4. Gordon DJ, Betlach TJ. Letter to committee leaders in the US Senate and House of Representatives. National Association of Medicaid Directors. Available at: http://medicaiddirectors.org/node/1083. Accessed December 5, 2014.
5. The Sovaldi® squeeze: high costs force tough state decisions. Available at: http://www.mhpa.org/-upload/SovaldiSqueeze-Oct2014.pdf. Accessed January 12, 2015.
6. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014; 160(5):293-300.
7. Spradling PR, Rupp L, Moorman AC, et al. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis. 2012; 55(8):1047-1055.
8. Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology. 2012;55(6): 1652-1661.
9. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N EnglJ Med. 2013;368(20):1859-1861.
10. Moorman AC, Gordon S, Rupp L, et al. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the Chronic Hepatitis Cohort Study. Clin Infect Dis. 2013;56(1):40-50.
11. Moorman AC, Xing J, Ko S, et al. Late diagnosis of hepatitis C virus infection in the Chronic Hepatitis Cohort Study (CHeCS) : missed opportunities for intervention. Hepatology. 2014;Epub ahead of print.
12. Holmberg SD, Lu M, Rupp L, et al. Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort Clin Infect Dis. 2013;57(2):240-246.
13. International Classification of Diseases, Ninth Revision, Clinical Modification. Hyattsville, MD: National Center for Health Statistics; 1980.
14. Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients. OPTN/SRTR 2012 Annual Data Report. Rockville, MD: US Department of Health and Human Services, Health Resources and Services Administration; 2014.
15. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection: comparison with liver biopsy and fibrot-est Hepatology. 2007;46(1):32-36.
16. Galbraith JW, Donnelly JP, Franco RA, Overton ET, Rodgers JB, Wang HE. National estimates of healthcare utilization by individuals with hepatitis C virus infection in the United States. Clin Infect Dis. 2014;59(6):755-764.
17. Xu F, Tong X, Leidner AJ. Hospital-izations and costs associated with hepatitis C and advanced liver disease continue to increase. Health Aff (Millwood). 2014; 33(10):1728-1735.
18. Ly KN, Speers S, Klevens RM, Barry V, Vogt TM. Measuring chronic liver disease mortality using an expanded cause of death definition and medical records in Connecticut, 2004. Hepatol Res. 2014;Epub ahead of print.
19. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156(4): 271-278.
20. Ly KN, Xing J, Klevens RM, Jiles RB, Holmberg SD. Causes of death and characteristics of decedents with viral hepatitis, United States, 2010. Clin Infect Dis. 2014;58(1):40-49.
21. Xu F, Xing J, Moorman AC, et al. FIB4 score and gender predict the incidence of hepatocellular carcinoma (HCC) among patients with chronic hepatitis C virus (HCV) infection: Chronic Hepatitis Cohort Study (CHeCS). Hepa-tology. 2014;60(4 suppl):905A; abstr 1471.